KA/EN
Register
Medicines reference
Search
Search
Active substance

Frunevetmab

Favourites

Anti-NGF monoclonal antibody. Registered in Georgia: 1 veterinary product. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Frunevetmab
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
1–2.8 mg/kg Cat Pain Associated with Osteoarthritis
Analgesia
 Subcutaneous monthly
Source: EMA EU Solensia product information
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Solensia 7 mg/ml solution for injection for cats - EU product information (SPC and package leaflet)
European Medicines Agency / Union Product Database, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in cats hypersensitive to frunevetmab or any excipient.
    Sources: Solensia EU SPC
  • Critical
    Do not use in cats under 12 months of age or under 2.5 kg.
    Sources: Solensia EU SPC
  • Critical
    Do not use in pregnant queens: anti-NGF antibodies were teratogenic and foetotoxic in monkey studies.
    Sources: Solensia EU SPC
  • Critical
    Do not use in lactating queens.
    Sources: Solensia EU SPC
  • Warning
    Do not use in cats intended for breeding.
    Sources: Solensia EU SPC
  • Caution
    Not studied in cats with IRIS stage 3 or 4 kidney disease; use only after a benefit-risk assessment.
    Sources: Solensia EU SPC · IRIS
  • Caution
    No safety data on use together with NSAIDs in cats.
    Sources: Solensia EU SPC
Latin name
Frunevetmab
Georgian name
ფრუნევეტმაბი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
1 of 1 forms
Products
Solensia
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Solensia, Solution

Frunevetmab 7 mg/ml, solution for injection for cats (1 ml vial)
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.0/10
Very good
vetman assessment

Solensia

Frunevetmab 7 mg/ml, solution for injection for cats (1 ml vial)
Assessed clinical scopeCat · Label-concordant monthly subcutaneous control of pain associated with clinically diagnosed osteoarthritis in a cat at least 12 months old and at least 2.5 kg; continue only while an individual clinically meaningful response persists · Subcutaneous
Care settingVeterinary-clinic monthly injection with baseline OA/pain assessment, whole-vial weight-band dosing, risk discussion and documented response/safety review before each repeat dose
vetman score 8.0/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · Verified on 22 Oct 2026

A strongly documented, licensed and practical monthly option for feline osteoarthritis pain, with meaningful but not universal benefit. The score is held below exceptional by modest efficacy separation and the expanded 2026 post-market safety signal; every repeat dose requires response and risk review.

Regulatory and scientific credibility9.5/10

Exact product identity and dosing are transparent, with active Georgian, central EU, GB and FDA veterinary authorisations, current regulatory assessments and multiple direct cat studies. Sponsor concentration is visible but does not erase the unusually strong exact-product dossier.

Clinical efficacy8.0/10

Randomized trials and two major regulatory reviews support monthly OA-pain benefit, including some objective activity evidence. Modest effect sizes, NNT 9 at day 56, high caregiver-placebo response, timepoint inconsistency and sponsor-linked development prevent a best-in-class efficacy score.

Safety and tolerability6.0/10

Controlled trials and PK characterise routine exposure, but skin disorders increased versus placebo and independent cases describe severe pruritic lesions with positive rechallenge. The October 2026 FDA label adds serious multi-system spontaneous reports, including death/euthanasia outcomes; incidence and causality cannot be estimated, and important comorbid/combination populations remain understudied.

Clinical practicality9.0/10

A single monthly clinic-administered SC dose, two simple whole-vial weight bands and no daily home medication make the regimen highly workable. Refrigeration, a monthly visit, fixed-vial boundaries, injection handling and response review are limited but real burdens.

Full-course cost-effectiveness-

Current verified Georgian monthly-course price is unavailable, so cost is excluded rather than guessed.

Important safety and use flags

  • Cat-only scope: control of pain from clinically diagnosed osteoarthritis. Solensia is analgesic and does not slow or reverse joint disease.
  • For this EU/Georgian presentation, do not use below 12 months or 2.5 kg. Do not transfer the younger US age threshold to this pack.
  • Do not use in breeding, pregnant or lactating cats.
  • Do not repeat after serious hypersensitivity. Anaphylaxis appears in the current FDA post-approval experience.
  • Before every injection, discuss current risks and document whether the cat has a clinically meaningful response; stop or choose another treatment when benefit is absent.
  • Monitor for severe pruritus, crusting, alopecia, dermatitis, ulceration or self-trauma. Clinically important or recurrent skin reactions require prompt investigation and reconsideration of treatment.
  • Current FDA post-market reports also include appetite/weight, gastrointestinal, neurologic, weakness/gait, urinary/renal and other signs. Spontaneous reports cannot establish frequency or causality, but serious events including death/euthanasia outcomes have been reported.
  • Safety and efficacy are not established in IRIS stage 3 or 4 kidney disease; perform an individual benefit-risk assessment and monitor appropriately.
  • Long-term concurrent NSAID safety in cats is not established. Review all medicines and any previous/current monoclonal-antibody therapy before each injection.
  • Store at 2-8°C protected from light; do not freeze or shake excessively. Use the whole vial for the exact weight band and a separate injection site for simultaneous vaccination.
Assessment sources
  1. EU Solensia product information2026
  2. FDA Solensia approval review2022
  3. FDA 2026 Solensia safety update2026
  4. Solensia GE register audit2026
  5. Solensia GB register audit2026
  6. Pivotal feline OA trial2021
  7. Multisite feline pilot trial2021
  8. Feline proof-of-concept trial2016
  9. Feline PK and immunogenicity2021
  10. Independent feline evidence review2023
  11. Frunevetmab cutaneous case series2023
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Frunevetmab7 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous
Manufacturer
Zoetis Belgium SA · Belgium
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: სოლენსია 7მგ/მლ
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ EU/2/20/269
Verified on: 22 Oct 2026
 UK Yes, veterinary
Verified on: 22 Oct 2026
 US Yes, veterinary
№ NADA 141-546
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified For label-concordant control of osteoarthritis pain in cats: 1-2.8 mg/kg SC once monthly using the exact whole-vial weight bands. For this EU/Georgian presentation, do not use below 12 months or 2.5 kg. Assess response before every repeat dose; Solensia relieves pain but does not slow or reverse osteoarthritis. Refrigerate at 2-8°C, protect from light, do not freeze or shake excessively.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗